目的 分析天津市第二人民醫(yī)院2010—2013年肝病治療口服中成藥的臨床用藥情況，探討用藥90%（DU 90%）在肝病治療口服中成藥利用評(píng)價(jià)中應(yīng)用的可行性和實(shí)用性，為臨床用藥的合理性和科學(xué)性提供參考。方法 收集、整理2010—2013年醫(yī)院肝病治療口服中成藥用藥頻度（DDDs）和限定日費(fèi)用（DDDc）進(jìn)行統(tǒng)計(jì)，分析DU 90%部分藥物的使用情況。結(jié)果 肝病治療口服中成藥的銷售金額呈逐年上升趨勢(shì)，增幅分別為21.70%、9.15%、26.43%；肝病治療口服中成藥的銷售金額排名靠前的藥物品種相對(duì)穩(wěn)定，大多為清熱解毒類、活血化瘀類和補(bǔ)益類藥物；DU 90%部分藥物的DDDs相對(duì)穩(wěn)定，銷售金額和DDDs的同步性較好。大部分藥品的DDDc較低，構(gòu)成比在2013年有所增加。結(jié)論 2010—2013年天津市第二人民醫(yī)院肝病治療口服中成藥使用情況基本合理，DU 90%可以作為一種有效的工具，應(yīng)用到處方的評(píng)價(jià)過(guò)程中。

Objective To analyze use of oral Chinese patent drugs for liver disease treatment in The Second People's Hospital of Tianjin during 2010—2013, and to discuss the feasibility and practicability of DU 90% in the evaluation of clinical drug utilization, so as to provide scientific evidence for the rational usage. Methods The utilization data including consumption sum, DDDs, and DDDc of oral Chinese patent drugs for liver disease treatments in The Second People's Hospital of Tianjin during 2010—2013 were analyzed statistically, and the use of DU 90% was analyzed. Results The consumption sum of oral Chinese patent drugs for liver disease treatment increased by 21.70%, 9.15%, and 26.43% from 2010 to 2013, and there was an upward trend. Drug varieties high ranking in the consumption sum were relatively stable, including antipyretic and antidote drugs, blood-activating, stasis-eliminating drugs and Qi-restoring drugs. DDDs of DU 90% drugs were relatively stable, and the sales sum and DDDs of synchronicity was better. DDDc of most drugs were low, and the composition ratio increased in 2013. Conclusion The use of oral Chinese patent drugs for liver disease treatment in The Second People's Hospital of Tianjin during 2010—2013 is basically reasonable, and DU 90% can be used as an effective tool, which is applied to the prescription of evaluation process.